Clinical trials: Multiple System Atrophy, MSA
Neuromuscular Diseases (NMD), ALS (Amyotrophic Lateral Sclerosis)
Invasive Home Ventilation in Denmark
The aim of this study is to describe national trends over the past 10 years in patients receiving invasive home mechanical ventilation (HMV) in Denmark.
- Conditions
- Neuromuscular Diseases (NMD), ALS (Amyotrophic Lateral Sclerosis), Spinal Cord Injuries (SCI), Duchenne Muscular Dystrophy (DMD)
- Trial name
- HOMEVENT DK (NCT07467187)
- Where
- Denmark
- Volunteers
- 450 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Multiple System Atrophy
Observational Study in Multiple System Atrophy
Talisman is global clinical study (20058N) in Multiple System Atrophy (MSA) patients. It will be conducted in two regions (China and the European Union [EU]).
- Trial name
- TALISMAN (NCT05453058)
- Testing
- plasma NfL and brain MRI (vMRI, DTI, and ASL [if feasible]) only for the EU cohort
- Where
- 8 sites in China
- Volunteers
- 90 people
- Sponsor
- H. Lundbeck A/S
Multiple System Atrophy
Efficacy of L-threo DOPS on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With MSA
Evaluate the effects of L-Threo DOPS on orthostatic hypotension symptoms and other non-motor symptoms in patients with Multiple System Atrophy (MSA) after 12 weeks following randomization to continued therapy with droxidopa or…
- Trial name
- DOPS-AMS (NCT02071459)
- Testing
- L-Threo DOPS
- Where
- 13 sites in France
- Volunteers
- 107 people
- Sponsor
- University Hospital, Toulouse
Multiple System Atrophy, Progressive Supranuclear Palsy
Neuroprotection and Natural History in Parkinson's Plus Syndromes (NNIPPS)
NNIPPS is a clinical trial of riluzole (a drug previously shown to slow down the rate of progression og amyotrophic lateral sclerosis-ALS; Lou Gehrig's disease) involving nearly 800 people diagnosed with the 'parkinson plus'…
- Trial name
- NCT00211224
- Testing
- Riluzole
- Where
- United Kingdom
- Volunteers
- 800 people
- Sponsor
- King's College London
Multiple System Atrophy
TRACK-MSA: A Longitudinal Study to Define Outcome Measures in Multiple System Atrophy
TRACK-MSA is an observational, non-interventional, longitudinal natural history study to define changes in clinical, neurological, blood, CSF, and neuroimaging biomarkers in patients with multiple system atrophy (MSA) comparing…
- Trial name
- NCT04450992
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- NYU Langone Health
Atypical Parkinsonism, MSA - Multiple System Atrophy
Integrated Management of Atypical Parkinsonism: A Home-based Patient-Centered Healthcare Delivery Based on Telenursing (IMPACT Study)
This project aims to investigate whether an integrated model based on proactive and reactive telenursing monitoring coordinated by a parkinsonism nurse specialist (case manager) is able to improve care delivery and quality of…
- Conditions
- Atypical Parkinsonism, MSA - Multiple System Atrophy, PSP, Nurse-Patient Relations
- Trial name
- NCT05792332
- Testing
- Telemonitoring, Standard-of-care
- Where
- 4 sites in Italy
- Volunteers
- 164 people
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Multiple System Atrophy (MSA)
Expanded Access Protocol of Verdiperstat in Patients With Multiple System Atrophy (MSA)
The purpose of this expanded access program is to provide access to the investigational drug verdiperstat in patients with Multiple System Atrophy (MSA).
- Trial name
- NCT05086094
- Testing
- BHV3241, verdiperstat
- Where
- United States
- Sponsor
- Biohaven Pharmaceuticals, Inc.
Multiple System Atrophy
GDNF Gene Therapy for Multiple System Atrophy
The objective of this randomized, double-blinded, placebo-controlled Phase 1 investigation is to evaluate the safety and potential clinical effect of AAV2-GDNF delivered to the putamen in subjects with either a possible or…
- Trial name
- NCT04680065
- Testing
- AAV2-GDNF gene therapy
- Where
- 7 sites in United States
- Volunteers
- 9 people
- Sponsor
- Brain Neurotherapy Bio, Inc.
Multiple System Atrophy
Therapeutic Education for Multiple System Atrophy (MSA) Patients and Their Caregivers
Multiple system atrophy (MSA) is a rare neurodegenerative disorder that leads to major disability, forcing patients and caregivers to adapt their environment and lifestyle.
- Trial name
- ETP@MS (NCT05819957)
- Testing
- Therapeutic Education Program (TEP)
- Where
- France
- Volunteers
- 15 people
- Sponsor
- University Hospital, Toulouse
Multiple System Atrophy
Comprehensive Swallowing Rehabilitation in Patients With MSA
The purpose of this study is to investigate the effect of comprehensive swallowing rehabilitation in patients with multiple system atrophy.
- Trial name
- NCT04782284
- Testing
- Comprehensive swallowing rehabilitation, Swallowing education
- Where
- South Korea
- Volunteers
- 24 people
- Sponsor
- Seoul National University Hospital
MSA - Multiple System Atrophy
MotIoN aDaptive Deep Brain Stimulation for MSA
Patients routinely undergo deep brain stimulation (DBS) for treatment of symptoms related to neurodegenerative conditions, most commonly Parkinson's disease.
- Trial name
- MINDS (NCT05197816)
- Testing
- Deep brain stimulation
- Where
- United Kingdom
- Volunteers
- 3 people
- Sponsor
- University of Oxford
PSP, PSP - Progressive Supranuclear Palsy
The CurePSP Genetics Program
This study is an observational, prospective genetic study. It aims to obtain DNA for research and testing from patients with PSP, CBS, MSA, and related neurological conditions and their families.
- Conditions
- PSP, PSP - Progressive Supranuclear Palsy, Corticobasal Syndrome, Corticobasal Syndrome(CBS)
- Trial name
- NCT06647641
- Testing
- Whole genome sequencing will be performed at the NIH
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
MSA
Mesenchymal Stem Cell Therapy in Multiple System Atrophy
The purpose of this study is to determine whether mesenchymal stem cells (MSCs) can be safely delivered to the cerebrospinal fluid (CSF) of patients with multiple system atrophy (MSA). Funding Source - FDA OOPD.
- Trial name
- NCT02315027
- Testing
- Autologous Mesenchymal Stem Cells
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic
Progressive Supranuclear Palsy, Parkinson Disease
Remote Monitoring in Progressive Supranuclear Palsy (PSP)
This is a single-arm, longitudinal, observational study on the use of wearable sensors and digital health technology to measure fall frequency and motor, speech, and cognitive function in patients with PSP over the course of…
- Conditions
- Progressive Supranuclear Palsy, Parkinson Disease, MSA - Multiple System Atrophy
- Trial name
- NCT04753320
- Where
- 2 sites in United States
- Volunteers
- 85 people
- Sponsor
- Massachusetts General Hospital
Parkinson Disease, MSA - Multiple System Atrophy
Manipulating and Optimising Brain Rhythms for Enhancement of Sleep
Treatment of sleep disturbances is mainly attempted through drug administration. However, certain drugs are associated with unwanted side effects or residual effects upon awakening (e.g.
- Conditions
- Parkinson Disease, MSA - Multiple System Atrophy, Chronic Pain, Epilepsy
- Trial name
- MORPHEUS (NCT05011773)
- Testing
- Deep brain stimulation
- Where
- United Kingdom
- Volunteers
- 4 people
- Sponsor
- University of Oxford
Parkinson's Disease (PD), Multiple System Atrophy (MSA)
[18F]ACI-15916 PET in α-synucleinopathies
The goal of this clinical trial is to test whether we can reliably and safely measure the accumulation of pathological protein α-synuclein [involved in some diseases such as Parkinson's disease, Lewy body dementia and Multiple…
- Conditions
- Parkinson's Disease (PD), Multiple System Atrophy (MSA), Dementia With Lewy Bodies (DLB)
- Trial name
- NCT06891703
- Testing
- [18F]ACI-15916
- Where
- Sweden
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- AC Immune SA
Symptomatic Neurogenic Orthostatic Hypotension (NOH), Parkinson's Disease
Fipamezole in Neurogenic Orthostatic Hypotension
The purpose of this study is to determine whether Fipamezole is effective in the treatment of orthostatic hypotension and related symptoms in multiple system atrophy and Parkinson's disease.
- Conditions
- Symptomatic Neurogenic Orthostatic Hypotension (NOH), Parkinson's Disease, Multiple System Atrophy
- Trial name
- Foehn (NCT00758849)
- Testing
- Fipamezole
- Where
- 4 sites in France, Portugal
- Volunteers
- 24 people
- Sponsor
- Juvantia Pharma Ltd
Essential Tremor, Multiple System Atrophy
Defining Phenotypes of Movement Disorders :Parkinson's Plus Disorders (PD), Essential Tremor (ET), Cortical Basal Degeneration (CBD), Multiple Systems Atrophy (MSA), Magnetoencephalography.
Investigators hypothesize that there are specific characteristic of each cognitive and motor condition that can be defined using brains scans.
- Conditions
- Essential Tremor, Multiple System Atrophy, Corticobasal Degeneration, Supranuclear Palsy, Progressive
- Trial name
- PHENO (NCT02132052)
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- University of Colorado, Denver
Neurogenic Orthostatic Hypotension, Multiple System Atrophy (MSA) With Orthostatic Hypotension
TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)
This multiple-center, 3-part, single-blind dose escalation (Part A), randomized, double-blind (Part B), and open-label multiple dose extension (Part C) study will be conducted in male and female subjects with neurogenic…
- Conditions
- Neurogenic Orthostatic Hypotension, Multiple System Atrophy (MSA) With Orthostatic Hypotension, Pure Autonomic Failure, Parkinson Disease
- Trial name
- NCT02705755
- Testing
- TD-9855
- Where
- 6 sites in United States
- Volunteers
- 34 people
- Sponsor
- Theravance Biopharma
Multiple System Atrophy
A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)
A Phase 2a Study of Foralumab Nasal in Patients with Multiple System Atrophy (MSA)
- Trial name
- NCT06868628
- Testing
- Foralumab Nasal
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Tiziana Life Sciences LTD